# US 2023/0053737 A1 · Traditional chinese medicine composition for treating egfr-tkis related skin rash and use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2023/0053737 A1 - Document ID: US20230053737A1 - Status: Published application - Kind: A1 - Application number: 17/787,337 - Filed: 2020-12-18 - Published: 2023-02-23 - Earliest claimed: 2019-12-20 - Assignees: Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd.; Yangtze River Pharmaceutical Group Co., Ltd.; Yangtze River Pharmaceutical Group Jiangsu Longfengtang Traditional Chinese Medicine Co., Ltd. - Applicants: Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd.; Yangtze River Pharmaceutical (Group) Co., Ltd.; Yangtze River Pharmaceutical Group Jiangsu Longfengtang Traditional Chinese Medicine Co., Ltd. - Inventors: Lizhu LIN - Web page: https://patentgrep.com/patent/US20230053737A1 ## CPC - A61K 36/288: Taraxacum (dandelion) - A61K 36/355: Lonicera (honeysuckle) - A61K 36/489: Sophora, e.g. necklacepod or mamani - A61K 36/534: Mentha (mint) - A61K 36/65: Paeoniaceae (Peony family), e.g. Chinese peony - A61K 36/71: Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal - A61K 36/75: Rutaceae (Rue family) - A61K 36/756: Phellodendron, e.g. corktree - A61P 17/00: Drugs for dermatological disorders - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract A traditional Chinese medicine composition for treating EGFR-TKIs related skin rash and a use thereof, characterized by comprising a therapeutically effective amount of the following components: honeysuckle, dandelion, radix sophorae flavescentis, Kochia scoparia, Dictamnus dasycarpus, tree peony root barks, Cortex Phellodendri, and peppermint. The traditional Chinese medicine composition for treating EGFR-TKIs related skin rash has a certain effect for the treatments of EGFR-TKIs related skin rash and paronychia. The raw materials coordinate with each other, thus can play medicinal effects to a maximum extent, thus significantly improving life quality of patients and prolonging survival period of patients. In addition, the traditional Chinese medicine composition also has advantages of non-toxic side effects and lower treatment cost. ## Claims ### Claim 1 A traditional Chinese medicine composition, comprising therapeutically effective amounts of following components: Lonicera japonica, Taraxacum mongolicum, Sophora flavescens, Kochiae fructus, dictamni cortex, moutan cortex, Phellodendri Chinensis Cortex, and Menthae Haplocalycis Herba; and the traditional Chinese medicine composition is used for treating EGFR-TKIs related skin rash. ### Claim 2 (depends on 1) The traditional Chinese medicine composition according to claim 1, comprising 5-40 parts of Lonicera japonica, 5-50 parts of Taraxacum mongolicum, 3-50 parts of Sophora flavescens, 5-50 parts of Kochiae fructus, 3-50 parts of dictamni cortex, 5-50 parts of moutan cortex, 5-50 parts of Phellodendri Chinensis Cortex, and 2-30 parts of Menthae Haplocalycis Herba. ### Claim 3 (depends on 1) The traditional Chinese medicine composition according to claim 1, comprising 15 parts of Lonicera japonica, 15 parts of Taraxacum mongolicum, 9 parts of Sophora flavescens, 15 parts of Kochiae fructus, 10 parts of dictamni cortex, 12 parts of moutan cortex, 12 parts of Phellodendri Chinensis Cortex, and 6 parts of Menthae Haplocalycis Herba. ### Claim 4 (depends on 1) A use of the traditional Chinese medicine composition according to claim 1 in preparation of a formulation for treating EGFR-TKIs related skin rash. ### Claim 5 (depends on 1) A use of the traditional Chinese medicine composition according to claim 1 in preparation of a formulation for treating EGFR-TKIs related paronychia. ### Claim 6 (depends on 4) The use of the traditional Chinese medicine composition according to claim 4, wherein the formulation is a liniment, a water aqua, a decoction, a granule, a paste, a mistura, an aerosol, a gel, an ointment, a facial mask, a cream or an unguent. ### Claim 7 (depends on 1) A method for treating EGFR-TKIs related skin rash or paronychia, comprising administering the traditional Chinese medicine composition according to claim 1 to a patient in need thereof, including a human. ### Claim 8 (depends on 2) A use of the traditional Chinese medicine composition according to claim 2 in preparation of a formulation for treating EGFR-TKIs related skin rash. ### Claim 9 (depends on 3) A use of the traditional Chinese medicine composition according to claim 3 in preparation of a formulation for treating EGFR-TKIs related skin rash. ### Claim 10 (depends on 2) A use of the traditional Chinese medicine composition according to claim 2 in preparation of a formulation for treating EGFR-TKIs related paronychia. ### Claim 11 (depends on 3) A use of the traditional Chinese medicine composition according to claim 3 in preparation of a formulation for treating EGFR-TKIs related paronychia. ### Claim 12 (depends on 5) The use of the traditional Chinese medicine composition according to claim 5, wherein the formulation is a liniment, a water aqua, a decoction, a granule, a paste, a mistura, an aerosol, a gel, an ointment, a facial mask, a cream or an unguent. ### Claim 13 (depends on 2) A method for treating EGFR-TKIs related skin rash or paronychia, comprising administering the traditional Chinese medicine composition according to claim 2 to a patient in need thereof, including a human. ### Claim 14 (depends on 3) A method for treating EGFR-TKIs related skin rash or paronychia, comprising administering the traditional Chinese medicine composition according to claim 3 to a patient in need thereof, including a human.